• About
  • Masthead
  • License Content
  • Advertise
  • Submit Press Release
  • RSS/Email List
  • Write for us
  • Contact us
2 Minute Medicine
No Result
View All Result

No products in the cart.

SUBSCRIBE
  • Specialties
    • Cardiology
    • Chronic Disease
    • Dermatology
    • Emergency
    • Endocrinology
    • Gastroenterology
    • Imaging and Intervention
    • Infectious Disease
    • Nephrology
    • Neurology
    • Obstetrics
    • Oncology
    • Ophthalmology
    • Pediatrics
    • Preclinical
    • Psychiatry
    • Public Health
    • Pulmonology
    • Rheumatology
    • Surgery
  • The Scan
  • Wellness
  • Classics™
    • 2MM+ Online Access
    • Paperback and Ebook
  • Rewinds
  • Visual
  • Partners
    • License Content
    • Submit Press Release
    • Advertise with Us
  • AccountLog-in/out
    • Subscribe
    • Sign-in
    • My account
2 Minute Medicine
  • Specialties
    • Cardiology
    • Chronic Disease
    • Dermatology
    • Emergency
    • Endocrinology
    • Gastroenterology
    • Imaging and Intervention
    • Infectious Disease
    • Nephrology
    • Neurology
    • Obstetrics
    • Oncology
    • Ophthalmology
    • Pediatrics
    • Preclinical
    • Psychiatry
    • Public Health
    • Pulmonology
    • Rheumatology
    • Surgery
  • The Scan
  • Wellness
  • Classics™
    • 2MM+ Online Access
    • Paperback and Ebook
  • Rewinds
  • Visual
  • Partners
    • License Content
    • Submit Press Release
    • Advertise with Us
  • AccountLog-in/out
    • Subscribe
    • Sign-in
    • My account
SUBSCRIBE
2 Minute Medicine
Subscribe
Home All Specialties Infectious Disease

Results from remdesivir compassionate use study for severe COVID-19

byThomas SuandDeepti Shroff Karhade
April 16, 2020
in Infectious Disease, Pulmonology
Reading Time: 3 mins read
0
Share on FacebookShare on Twitter

1. In this study, nearly 70% of patients who received remdesivir for compassionate use had an improvement in oxygen-support class and over half of intubated patients were able to be extubated.

2. As there was no control arm to the study, it is difficult to determine the true efficacy of remdesivir.

Evidence Rating Level: 3 (Average)

Study Rundown: The severity of symptoms of COVID-19 varies widely, but SARS-nCov-2 infection can quickly lead to life-threatening complications including acute respiratory distress syndrome and multisystem organ failure. Because there is currently no definitive treatment, disease management is limited to supportive care, such as supplemental oxygen and antibiotics, and experimental therapies including retroviral agents, antiinflammatory compounds, and convalescent plasma. Remdesivir is a broad-spectrum nucleotide analog prodrug that has shown in vitro activity against SARS-nCov-2 as well as a favorable clinical safety profile in patients treated for acute Ebola virus infection. In this study, remdesivir was provided on a compassionate-use basis to patients hospitalized with severe COVID-19, and incidence of key clinical events were tracked for four weeks. By the end of the trial, nearly 70% of patients showed an improvement in degree of oxygen support, and the majority of patients who were receiving invasive mechanical ventilation were extubated. These findings were independent of sex, comorbidities, and duration of symptoms before initiation of treatment. Over half of the patients experienced adverse events, and over a tenth died despite remdesivir treatment. This study had several limitations including the small size of the cohort, low patient retention, and the lack of both a control group and prespecified endpoints. Although the results are promising, larger-scale randomized controlled trials will offer stronger evidence regarding the use of remdesivir to treat patients with COVID-19.

Click here to read the study in NEJM

Relevant Reading: Covid-19 — The Search for Effective Therapy

In-Depth [prospective cohort]: In this multinational compassionate-use study, 61 patients were approved by Gilead Sciences to receive a 10-day course of remdesivir, consisting of a loading dose of 200 mg intravenously on the first day and 100 mg daily for the remaining 9 days. Eligibility criteria included hospitalization with reverse-transcriptase polymerase chain reaction (RT-PCR) confirmed SARS-nCov-2 infection in addition to either an oxygen saturation of 94% or less on ambient air or a need for oxygen support. Patients were not permitted to use other investigational agents during the trial. 8 patients who received the initial dose were excluded from final analyses due to missing postbaseline information. Of the 53 remaining patients, 10 received 5 to 9 days of treatment and 3 received fewer than 5 days. 36 patients (68%) showed an improvement in oxygen support class while 8 (15%) showed worsening. 17 of 30 (57%) patients who were originally receiving invasive ventilation were extubated, and 3 of 4 who were receiving extracorporeal membrane oxygenation were able to be removed. The cumulative incidence of clinical improvement, defined as live discharge or a decrease of at least 2 points on a 6 point ordinal scale, was 84% (95% confidence interval [CI], 70 to 99), but clinical improvement was less frequent among older patients as well as those receiving invasive mechanical ventilation. 60% of patients reported adverse events, the most common being increased hepatic enzymes, diarrhea, rash, renal impairment, and hypotension, and 23% of patients experienced serious adverse events. Overall mortality was 0.56 per 100 hospitalization days (95% CI, 0.14 to 0.97).

RELATED REPORTS

Unvaccinated status increases risk of long COVID symptoms

2 Minute Medicine Rewind January 23, 2023

The 2 Minute Medicine Podcast Episode 6

Image: PD

©2020 2 Minute Medicine, Inc. All rights reserved. No works may be reproduced without expressed written consent from 2 Minute Medicine, Inc. Inquire about licensing here. No article should be construed as medical advice and is not intended as such by the authors or by 2 Minute Medicine, Inc.

Tags: compassionate useCoronavirusintubationremdesivirSARS-CoV-2
Previous Post

Risk of dementia with air pollution exposure amplified in patients with heart disease

Next Post

Addition of claims-based frailty index enhances current Medicare cost prediction model

RelatedReports

Medical vaccine exemptions increase after elimination of nonmedical exemptions
Infectious Disease

Unvaccinated status increases risk of long COVID symptoms

January 25, 2023
Many new pediatric asthma cases attributable to obesity
Weekly Rewinds

2 Minute Medicine Rewind January 23, 2023

January 23, 2023
2MM Podcast

The 2 Minute Medicine Podcast Episode 6

January 13, 2023
Emergency

Dexmedetomidine premedication increases preoperative sedation and inhibits stress induced by tracheal intubation

January 17, 2023
Next Post

Addition of claims-based frailty index enhances current Medicare cost prediction model

The SOLO1 trial: Olaparib significantly delays progression of advanced ovarian cancer

Decreased risk of ovarian cancer in women who have breastfed

#VisualAbstract: A Randomized, Controlled Trial of Liraglutide for Adolescents with Obesity

#VisualAbstract: A Randomized, Controlled Trial of Liraglutide for Adolescents with Obesity

License Our Award-Winning Physician-Written Medical News and Visual Abstracts

2 Minute Medicine is the leading authoritative medical news licensing service, and the only with reports written by practicing doctors.

LICENSE CONTENT

2MM+ Premium Access

No ads & unlimited access to all current reports, over 9000 searchable archived reports, visual abstracts, Weekly Rewinds, and the online edition of The Classics Series™ textbook.

Subscription Options
2 Minute Medicine

2 Minute Medicine® is an award winning, physician-run, expert medical media company. Our content is curated, written and edited by practicing health professionals who have clinical and scientific expertise in their field of reporting. Our editorial management team is comprised of highly-trained MD physicians. Join numerous brands, companies, and hospitals who trust our licensed content.

Recent Reports

  • BNT162b2 booster is safe and reduces COVID-19 transmission in older adults
  • Bisphosphonates, denosumab, abaloparatide, teriparatide, and romosozumab reduce postmenopausal fracture risk
  • Epstein-Barr viral load monitoring reduces risk of post-liver transplant lymphoproliferative disease
License Content
Terms of Use | Disclaimer
Cookie Policy
Privacy Statement (EU)
Disclaimer

© 2021 2 Minute Medicine, Inc. - Physician-written medical news.

  • Specialties
    • Cardiology
    • Chronic Disease
    • Dermatology
    • Emergency
    • Endocrinology
    • Gastroenterology
    • Imaging and Intervention
    • Infectious Disease
    • Nephrology
    • Neurology
    • Obstetrics
    • Oncology
    • Ophthalmology
    • Pediatrics
    • Preclinical
    • Psychiatry
    • Public Health
    • Pulmonology
    • Rheumatology
    • Surgery
  • The Scan
  • Wellness
  • Classics™
    • 2MM+ Online Access
    • Paperback and Ebook
  • Rewinds
  • Visual
  • Partners
    • License Content
    • Submit Press Release
    • Advertise with Us
  • Account
    • Subscribe
    • Sign-in
    • My account

© 2021 2 Minute Medicine, Inc. - Physician-written medical news.

Want more physician-written
medical news?

Join over 10 million yearly readers and numerous companies. For healthcare professionals
and the public.

Subscribe for free today!

Subscription options